FAP and neoplasm: We further discuss the possible limitations and risks stemming from the increased bioavailability of DPP-IV substrates in tumor niches and/or so far rather poorly understood other effects of DPP-IV inhibition, such as the activation of the nuclear factor E2–related factor 2 (Nrf2)-mediated antioxidant response [7,8].